HT-3 is a human cervical carcinoma cell line that grows in adherent culture. Although this cell line was initially classified as human papillomavirus (HPV) DNA negative, subsequent studies revealed that the cells harbor HPV30 DNA in their genome. The HT-3 cells have a homozygous mutation in the TP53 gene, resulting in the expression of the transactivation-defective, dominant negative form of the protein. These cells form tumors when injected subcutaneously into immunocompromised mice.
This cell line was established in 1963 from a metastatic site (lymph node) in a 53-year-old Caucasian female.
Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
- Naeger LK et al. (1999) Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein. Cell Growth & Differentiation 10: 413-422 (PubMed ID: 10392903)
- Xiao X et al (2012) Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecologic Oncology 127: 249-255 (PubMed ID: 22735790)
This cell line may be licensed nonexclusively for research or commercial purposes.
Tingting Zhang-Kharas, PhD